Compare Enveric Biosciences Inc (ENVB) vs ING Groep NV (ING) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs ING Groep NV — how do they compare? Enveric Biosciences Inc trades at $1.45 (market cap $6.20M), while ING Groep NV trades at $35.34 (market cap $101.24B). The key difference: ING Groep NV is far larger — about 16329× Enveric Biosciences Inc's market cap, and ING Groep NV pays a 3.74% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | ING | |
|---|---|---|
Market Cap | $6.20M | $101.24B |
Sector | Health | Financials |
52-Week High | $17.40 | $35.92 |
52-Week Low | $1.27 | $23.66 |
Enterprise Value | $1.30M | — |
Dividend Yield | — | 3.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.55, down 0.64% with a bullish technical signal despite negative profitability. The company shows promising clinical progress with its lead candidate EB-003, supported by recent FDA guidance and positive preclinical data. While quarterly earnings consistently beat expectations, the company remains unprofitable with negative ROE and ROA. Analyst sentiment is positive with 75% buy ratings.
Investment outlook hinges on successful drug development milestones, with regulatory progress and intellectual property expansion providing catalysts. Key risks include clinical trial outcomes, cash burn from operations, and dependence on financing activities. The stock presents speculative growth potential for risk-tolerant investors focused on biotech innovation.
ING trades at $35.68, down slightly by 0.08% on the day, with a bullish technical signal from moving averages and a neutral oscillator reading. The company reported strong Q2 2026 earnings, beating estimates with EPS of $0.79 versus $0.75 expected, and raised its full-year revenue guidance. Analyst consensus is strongly positive with 10 buy ratings and no sell ratings out of 16 analysts.
The outlook for ING is favorable, supported by earnings momentum and strategic initiatives, though risks include negative cash flow trends and potential market volatility. The stock presents a value opportunity with a P/E of 13.37 and a net income margin of 28.34%, but investors should weigh the persistent cash flow deficits against growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →
